Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies

Phys Med Biol. 2007 Jul 7;52(13):3665-77. doi: 10.1088/0031-9155/52/13/001. Epub 2007 May 24.

Abstract

Tumors cannot grow beyond a certain size (about 1-2 mm in diameter) through simple diffusion of oxygen and other essential nutrients into the tumor. Angiogenesis, the formation of blood vessels from pre-existing vessels, is a crucial and observed step, through which a tumor obtains its own blood supply. Thus, strategies that interfere with the development of this tumor vasculature, known as anti-angiogenic therapy, represent a novel approach to controlling tumor growth. Several pre-clinical studies have suggested that currently available angiogenesis inhibitors are unlikely to yield significant sustained improvements in tumor control on their own, but rather will need to be used in combination with conventional treatments to achieve maximal benefit. Optimal sequencing of anti-angiogenic treatment and radiotherapy or chemotherapy is essential to the success of these combined treatment strategies. Hence, a major challenge to mathematical modeling and computer simulations is to find appropriate dosages, schedules and sequencing of combination therapies to control or eliminate tumor growth. Here, we present a mathematical model that incorporates tumor cells and the vascular network, as well as their interplay. We can then include the effects of two different treatments, conventional cytotoxic therapy and anti-angiogenic therapy. The results are compared with available experimental and clinical data.

MeSH terms

  • Algorithms
  • Angiogenesis Inhibitors / pharmacology*
  • Humans
  • Models, Statistical
  • Models, Theoretical
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neoplasms / radiotherapy*
  • Neovascularization, Pathologic*
  • Normal Distribution

Substances

  • Angiogenesis Inhibitors